{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:02:18Z","timestamp":1789642938492,"version":"4.0.0"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bladder cancer (BC), a highly prevalent malignancy of the urinary tract, imposes a considerable clinical burden because of its high recurrence rates and a substantial risk of disease progression. Accumulating evidence suggests that microbiome dysbiosis is associated with the initiation and progression of BC through potentially bidirectional interactions. Recent advances in high-throughput sequencing technologies have facilitated a more comprehensive characterization of the urinary microbiome, thereby revealing its potential involvement in the pathogenesis of BC. This review summarizes the proposed mechanisms through which microbial communities may contribute to BC carcinogenesis, including chronic inflammation, microbial metabolite production, and epigenetic regulation. We further critically evaluate the established mechanisms of Bacillus Calmette\u2013Gu\u00e9rin (BCG) immunotherapy\u2014a standard intravesical immunotherapy for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC)\u2014and examine the emerging application of microbiome profiling as a source of candidate noninvasive biomarkers and potential correlates or modulators of immune checkpoint inhibitor (ICI) response. Additionally, we elucidate the associations between microbiota heterogeneity and immunotherapy response, offering novel insights into microbiome-targeted therapeutic strategies for BC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1920567","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:10:29Z","timestamp":1789639829000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of microbiome-immune interactions in bladder cancer and targeted regulatory strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Songhong","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital of Kunming Medical University","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, screening, and prevention of bladder cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11157","DOI":"10.3390\/ijms252011157","article-title":"Differential urinary microbiome and its metabolic footprint in bladder cancer patients following BCG treatment","volume":"25","author":"Min","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/ijms25031732","article-title":"The urinary microbiome in health and disease: Relevance for bladder cancer","volume":"25","author":"Kustrimovic","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3233\/blc-200277","article-title":"The urinary microbiome and bladder cancer: Susceptibility and immune responsiveness","volume":"6","author":"Andolfi","year":"2020","journal-title":"Bladder Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.13","article-title":"Microbiota: a key orchestrator of cancer therapy","volume":"17","author":"Roy","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02126-6","article-title":"Microbiota-shaped neutrophil senescence regulates sexual dimorphism in bladder cancer","volume":"26","author":"Zhu","year":"2025","journal-title":"Nat Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5213\/inj.1938244.122","article-title":"The urine microbiome of healthy men and women differs by urine collection method","volume":"24","author":"Pohl","year":"2020","journal-title":"Int Neurourol J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02164-24","article-title":"Evaluating the use of biobanked urine specimens for human urobiome studies","volume":"13","author":"Mukherjee","year":"2025","journal-title":"Microbiol Spectr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/ijms23031336","article-title":"Determination of the optimal bacterial DNA extraction method to explore the urinary microbiota","volume":"23","author":"Vendrell","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e00290-19","DOI":"10.1128\/mSystems.00290-19","article-title":"Controlling for contaminants in low-biomass 16S rRNA gene sequencing experiments","volume":"4","author":"Karstens","year":"2019","journal-title":"mSystems"},{"key":"B13","doi-asserted-by":"publisher","first-page":"12157","DOI":"10.1038\/s41598-018-29054-w","article-title":"The urinary microbiome associated with bladder cancer","volume":"8","author":"Bu\u010devi\u0107 Popovi\u0107","year":"2018","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00167","article-title":"Profiling the urinary microbiota in male patients with bladder cancer in China","volume":"8","author":"Wu","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11042","DOI":"10.1038\/s41598-020-67443-2","article-title":"Bladder cancer-related microbiota: examining differences in urine and tissue samples","volume":"10","author":"Mansour","year":"2020","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/biomedicines10071758","article-title":"Bladder tissue microbiome composition in patients of bladder cancer or benign prostatic hyperplasia and related human beta defensin levels","volume":"10","author":"Mansour","year":"2022","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-023-04627-1","article-title":"Does the urinary microbiome profile change after treatment of bladder cancer","volume":"41","author":"Hussein","year":"2023","journal-title":"World J Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.5114\/pjp.2019.84458","article-title":"Environment and urinary bladder cancer. A historical perspective","volume":"70","author":"Nesi","year":"2019","journal-title":"Pol J Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.03.052","article-title":"Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer","volume":"157","author":"Cunningham","year":"2014","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.12.010","article-title":"Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens","volume":"86","author":"Yacouba","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.677605","article-title":"Can smoking cause differences in urine microbiome in male patients with bladder cancer? A retrospective study","volume":"11","author":"Ma","year":"2021","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.12.043","article-title":"The microbiome and genitourinary cancer: A collaborative review","volume":"75","author":"Markowski","year":"2019","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrurol.2015.292","article-title":"The interplay of extracellular matrix and microbiome in urothelial bladder cancer","volume":"13","author":"Alfano","year":"2016","journal-title":"Nat Rev Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1630726","article-title":"From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1716230","article-title":"The infection-microbiome-immunity axis in bladder cancer: mechanistic insights and therapeutic perspectives","volume":"16","author":"Pan","year":"2025","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mi.2014.44","article-title":"Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway","volume":"8","author":"Park","year":"2015","journal-title":"Mucosal Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395580","article-title":"Gut microbiota and interstitial cystitis: exploring the gut-bladder axis through mendelian randomization, biological annotation and bulk RNA sequencing","volume":"15","author":"Fu","year":"2024","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.3390\/jcm10153354","article-title":"Intestinal microbial metabolites in ankylosing spondylitis","volume":"10","author":"Scalise","year":"2021","journal-title":"J Clin Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116172","article-title":"TDO2 promotes bladder cancer progression via AhR-mediated SPARC\/FILIP1L signaling","volume":"223","author":"Ding","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1711299","article-title":"Lung-gut axis, intestinal microbiota, and pulmonary fibrosis: mechanisms and therapeutic potential","volume":"16","author":"Yang","year":"2025","journal-title":"Front Microbiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.20517\/mrr.2023.47","article-title":"The role of microbiota in tumorigenesis, progression and treatment of bladder cancer","volume":"3","author":"Peng","year":"2024","journal-title":"Microbiome Res Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16275","article-title":"Nucleocytoplasmic \u03b2-catenin expression contributes to neuroendocrine differentiation in muscle invasive bladder cancer","volume":"115","author":"Akman","year":"2024","journal-title":"Cancer Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.24.10111","article-title":"Regulation of protein stability by GSK3 mediated phosphorylation","volume":"8","author":"Xu","year":"2009","journal-title":"Cell Cycle"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01429","article-title":"Butyrate conditions human dendritic cells to prime type 1 regulatory T cells via both histone deacetylase inhibition and G protein-coupled receptor 109A signaling","volume":"8","author":"Kaisar","year":"2017","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101478","article-title":"Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy","volume":"5","author":"Kang","year":"2024","journal-title":"Cell Rep Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"10558","DOI":"10.3390\/ijms262110558","article-title":"The urinary microbiota and the gut-bladder axis in bladder cancer","volume":"26","author":"Butt","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01326-2","article-title":"The gut microbiota in cancer immunity and immunotherapy","volume":"22","author":"Xie","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/11795549231206796","article-title":"Is the urinary and gut microbiome associated with bladder cancer","volume":"17","author":"Chorbi\u0144ska","year":"2023","journal-title":"Clin Med Insights Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.3390\/genes13111967","article-title":"Integrated analysis of the fecal metagenome and metabolome in bladder cancer in a Chinese population","volume":"13","author":"Qin","year":"2022","journal-title":"Genes (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1479795","article-title":"Urinary microbiota changes among NMIBC patients during BCG therapy: comparing BCG responders and non-responders","volume":"15","author":"Boban","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.12.014","article-title":"Stool microbiome signature associated with response to neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer","volume":"85","author":"Pederzoli","year":"2024","journal-title":"Eur Urol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.06.061","article-title":"Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab","volume":"78","author":"Hopkins","year":"2020","journal-title":"Eur Urol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01011-z","article-title":"The role of the urinary microbiome in genitourinary cancers","volume":"22","author":"Lee","year":"2025","journal-title":"Nat Rev Urol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.Crc-23-0479","article-title":"Role of gut microbiome in neoadjuvant chemotherapy response in urothelial carcinoma: A multi-institutional prospective cohort evaluation","volume":"4","author":"Bukavina","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B45","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/apm.13011","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections","volume":"128","author":"Larsen","year":"2020","journal-title":"Apmis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12672-025-02509-z","article-title":"The role of TLR-4 in chemoresistance of cancer","volume":"16","author":"Li","year":"2025","journal-title":"Discov Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.12659\/msm.906857","article-title":"Toll-like receptor 4 (TLR4)\/Cyclooxygenase-2 (COX-2) regulates prostate cancer cell proliferation, migration, and invasion by NF-\u03baB activation","volume":"24","author":"Wang","year":"2018","journal-title":"Med Sci Monit"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-0304","article-title":"Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01371","article-title":"Myeloid-derived suppressor cells in tumors: From mechanisms to antigen specificity and microenvironmental regulation","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e181243","DOI":"10.1172\/jci181243","article-title":"Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs","volume":"135","author":"Liao","year":"2025","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.3390\/cancers14215317","article-title":"Gut microbiota and tumor immune escape: A new perspective for improving tumor immunotherapy","volume":"14","author":"He","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.chom.2013.07.012","article-title":"Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin\/\u03b2-catenin signaling via its FadA adhesin","volume":"14","author":"Rubinstein","year":"2013","journal-title":"Cell Host Microbe"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00041.2019","article-title":"The urothelium: Life in a liquid environment","volume":"100","author":"Dalghi","year":"2020","journal-title":"Physiol Rev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"18024","DOI":"10.1038\/s41598-020-74390-5","article-title":"Escherichia coli foster bladder cancer cell line progression via epithelial mesenchymal transition, stemness and metabolic reprogramming","volume":"10","author":"Abd-El-Raouf","year":"2020","journal-title":"Sci Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.3390\/ijms22094483","article-title":"The interplay between oxidative stress, inflammation and angiogenesis in bladder cancer development","volume":"22","author":"Wigner","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009310","article-title":"Uropathogenic E. coli induces DNA damage in the bladder","volume":"17","author":"Chagneau","year":"2021","journal-title":"PLoS Pathog"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.10.23287127","article-title":"Genotoxic colibactin mutational signature in colorectal cancer is associated with clinicopathological features, specific genomic alterations and better survival","author":"Georgeson","year":"2024","journal-title":"medRxiv"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(82)90153-5","article-title":"Association of bacteriuria and urinary nitrosamine formation with Schistosoma haematobium infection in the Qalyub area of Egypt","volume":"76","author":"Hicks","year":"1982","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2020.61.4.338","article-title":"The microbiome in urological diseases","volume":"61","author":"Lee","year":"2020","journal-title":"Investig Clin Urol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-7-19","article-title":"Role of chronic E. coli infection in the process of bladder cancer- an experimental study","volume":"7","author":"El-Mosalamy","year":"2012","journal-title":"Infect Agent Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/cancers13010127","article-title":"MicroRNA-mediated metabolic shaping of the tumor microenvironment","volume":"13","author":"Virga","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"B63","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3390\/pathogens10060765","article-title":"Human single-chain antibodies that neutralize elastolytic activity of Pseudomonas aeruginosa LasB","volume":"10","author":"Santajit","year":"2021","journal-title":"Pathogens"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1128\/iai.56.11.2925-2932.1988","article-title":"Pseudomonas aeruginosa alkaline protease degrades human gamma interferon and inhibits its bioactivity","volume":"56","author":"Horvat","year":"1988","journal-title":"Infect Immun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.041","article-title":"From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites","volume":"165","author":"Koh","year":"2016","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1089\/biores.2012.0223","article-title":"Butyrate histone deacetylase inhibitors","volume":"1","author":"Steliou","year":"2012","journal-title":"Biores Open Access"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-011-0322-2","article-title":"Apoptosis of bladder cancer by sodium butyrate and cisplatin","volume":"18","author":"Maruyama","year":"2012","journal-title":"J Infect Chemother"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA118.000752","article-title":"Butyrate suppresses the proliferation of colorectal cancer cells via targeting pyruvate kinase M2 and metabolic reprogramming","volume":"17","author":"Li","year":"2018","journal-title":"Mol Cell Proteomics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"14430","DOI":"10.1038\/s41598-018-32860-x","article-title":"Regulation of the effector function of CD8(+) T cells by gut microbiota-derived metabolite butyrate","volume":"8","author":"Luu","year":"2018","journal-title":"Sci Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.7150\/thno.119304","article-title":"Short-chain fatty acids in the tumor microenvironment: From molecular mechanisms to cancer therapy","volume":"16","author":"Xiang","year":"2026","journal-title":"Theranostics"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12790","article-title":"The detrimental impact of extracellular bacterial proteases on wound healing","volume":"14","author":"Lindsay","year":"2017","journal-title":"Int Wound J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00939-15","article-title":"The LasB elastase of Pseudomonas aeruginosa acts in concert with alkaline protease AprA to prevent flagellin-mediated immune recognition","volume":"84","author":"Casilag","year":"2016","journal-title":"Infect Immun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.7150\/thno.101575","article-title":"SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3\/CCL2\/IL-6 axis and is regulated by VEZF1","volume":"14","author":"Li","year":"2024","journal-title":"Theranostics"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-22-2485","article-title":"The m6A reader YTHDF2 promotes bladder cancer progression by suppressing RIG-I-mediated immune response","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2024.100146","article-title":"PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy","volume":"3","author":"Liu","year":"2024","journal-title":"Cell Insight"},{"key":"B76","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41419-025-07593-1","article-title":"PLA2G7 promotes immune evasion of bladder cancer through the JAK-STAT-PDL1 axis","volume":"16","author":"Peng","year":"2025","journal-title":"Cell Death Dis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10238-026-02098-3","article-title":"Immune checkpoint inhibitors in bladder cancer: From mechanistic insights to emerging combination frontlines","volume":"26","author":"Ajalli","year":"2026","journal-title":"Clin Exp Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"22198","DOI":"10.1038\/s41598-024-72918-7","article-title":"Intratumoral microbiota as a novel prognostic indicator in bladder cancer","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci Rep"},{"key":"B81","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1186\/s12866-025-04367-9","article-title":"Urinary microbiome in non-muscle invasive bladder cancer: Impact of sample types and sex differences","volume":"25","author":"Kang","year":"2025","journal-title":"BMC Microbiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1186\/s12967-024-05446-7","article-title":"Urinary microbiome dysbiosis is associated with an inflammatory environment and perturbed fatty acids metabolism in the pathogenesis of bladder cancer","volume":"22","author":"Wu","year":"2024","journal-title":"J Transl Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03916-x","article-title":"Tumor-colonizing Lachnoclostridium-mediated chemokine expression enhances the immune infiltration of bladder urothelial carcinoma","volume":"74","author":"Chen","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-021-00659-0","article-title":"Deciphering the influence of urinary microbiota on FoxP3+\u2009regulatory T cell infiltration and prognosis in Chinese patients with non-muscle-invasive bladder cancer","volume":"35","author":"Qiu","year":"2022","journal-title":"Hum Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-021-02407-8","article-title":"Urogenital microbiota: Potentially important determinant of PD-L1 expression in male patients with non-muscle invasive bladder cancer","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Microbiol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5489\/cuaj.8341","article-title":"Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC","volume":"18","author":"Garneau","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-12-1882","article-title":"Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells","volume":"73","author":"Redelman-Sidi","year":"2013","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"291.e1","DOI":"10.1016\/j.urolonc.2024.04.011","article-title":"An exploratory study investigating the impact of the bladder tumor microbiome on Bacillus Calmette Guerin (BCG) response in non-muscle invasive bladder cancer","volume":"42","author":"Knorr","year":"2024","journal-title":"Urol Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2026.168192","article-title":"Urinary microbiome and metabolomic profiling reveal propionic acid as an enhancer of BCG immunotherapy in bladder cancer","volume":"1872","author":"Liu","year":"2026","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3390\/diagnostics12092068","article-title":"The urinary microbiome: Role in bladder cancer and treatment","volume":"12","author":"Friedrich","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/ijms25010144","article-title":"Longitudinal transcription profiling of bladder cancers dictate the response to BCG treatment and disease progression","volume":"25","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807271","article-title":"Targeting tryptophan catabolism in cancer immunotherapy era: Challenges and perspectives","volume":"13","author":"Peyraud","year":"2022","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1945-z","article-title":"Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer","volume":"66","author":"Pichler","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1080\/2090598x.2023.2190687","article-title":"Can we offer additional BCG therapy for three-month BCG refractory high grade\/T1, Tis bladder cancer patients","volume":"21","author":"Elsawy","year":"2023","journal-title":"Arab J Urol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30496-x","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00339","article-title":"Progress and challenges in precise treatment of tumors with PD-1\/PD-L1 blockade","volume":"11","author":"Jiang","year":"2020","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41522-025-00819-2","article-title":"Microbiome meets immunotherapy: Unlocking the hidden predictors of immune checkpoint inhibitors","volume":"11","author":"Huang","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e20192282","DOI":"10.1084\/jem.20192282","article-title":"Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling","volume":"217","author":"Shi","year":"2020","journal-title":"J Exp Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"B102","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1186\/s12967-024-05762-y","article-title":"Blautia coccoides and its metabolic products enhance the efficacy of bladder cancer immunotherapy by promoting CD8(+) T cell infiltration","volume":"22","author":"Wang","year":"2024","journal-title":"J Transl Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.03.016","article-title":"Antibiotic exposure and immune checkpoint inhibitors in patients with NSCLC: The backbone matters","volume":"17","author":"Cortellini","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"160.e11","DOI":"10.1016\/j.urolonc.2023.11.017","article-title":"Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma: A systematic review and meta-analysis","volume":"42","author":"Febriyanto","year":"2024","journal-title":"Urol Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.789078","article-title":"Phase I clinical trial of an autologous dendritic cell vaccine against HER2 shows safety and preliminary clinical efficacy","volume":"11","author":"Maeng","year":"2021","journal-title":"Front Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.4137\/cmo.S7658","article-title":"Antitumor efficacy of intravesical BCG, gemcitabine, interferon-\u03b1 and interleukin-2 as mono- or combination-therapy for bladder cancer in an orthotopic tumor model","volume":"5","author":"Xiao","year":"2011","journal-title":"Clin Med Insights Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette-Gu\u00e9rin immunotherapy: From cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.36.4.1638","article-title":"Diagnostic accuracy of NMP 22 and urine cytology for detection of transitional cell carcinoma urinary bladder taking cystoscopy as gold standard","volume":"36","author":"Sajid","year":"2020","journal-title":"Pak J Med Sci"},{"key":"B109","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/s12866-025-04455-w","article-title":"XGBoost-based urinary microbial signatures enable non-invasive diagnosis and prognosis for urothelial carcinoma","volume":"25","author":"Xie","year":"2025","journal-title":"BMC Microbiol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001058","article-title":"Urinary microbiota - a potential biomarker and therapeutic target for bladder cancer","volume":"68","author":"Bi","year":"2019","journal-title":"J Med Microbiol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.3390\/jcm13164927","article-title":"Insights into the interplay between the urinary microbiome and bladder cancer: A comprehensive review","volume":"13","author":"Pallares-Mendez","year":"2024","journal-title":"J Clin Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2025.103065","article-title":"Fusobacterium nucleatum promotes bladder cancer progression and immune escape by activating the IL22\/STAT3\/PD-L1 signaling cascade","volume":"97","author":"Yang","year":"2025","journal-title":"Tissue Cell"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3390\/medicina61081401","article-title":"Microbiome shifts in bladder cancer: A narrative review of urobiome composition, progression, and therapeutic impact","volume":"61","author":"Gherasim","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B114","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s12885-025-13817-6","article-title":"The role of urinary microbiota in primary and recurrent bladder cancer: Insights from a propensity score matching study","volume":"25","author":"Sheng","year":"2025","journal-title":"BMC Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114086","article-title":"T cell cascade regulation initiates systemic antitumor immunity through living drug factory of anti-PD-1\/IL-12 engineered probiotics","volume":"43","author":"Liao","year":"2024","journal-title":"Cell Rep"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-155","article-title":"A novel Bifidobacterium infantis-mediated TK\/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer","volume":"28","author":"Tang","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/cgt.2012.86","article-title":"Bifidobacterium infantis-mediated HSV-TK\/GCV suicide gene therapy induces both extrinsic and intrinsic apoptosis in a rat model of bladder cancer","volume":"20","author":"Yin","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"B118","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12866-024-03372-8","article-title":"Gut microbiota Parabacteroides distasonis enchances the efficacy of immunotherapy for bladder cancer by activating anti-tumor immune responses","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Microbiol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01426.x","article-title":"Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors","volume":"101","author":"Seow","year":"2010","journal-title":"Cancer Sci"},{"key":"B120","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.3390\/cancers15235551","article-title":"Bladder cancer and probiotics: What do we know so far","volume":"15","author":"S\u00e1nchez-Pellicer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B121","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12916-025-04183-y","article-title":"Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors","volume":"23","author":"Lin","year":"2025","journal-title":"BMC Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-25-0873","article-title":"Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression","volume":"14","author":"Yang","year":"2026","journal-title":"Cancer Immunol Res"},{"key":"B123","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3390\/life13030812","article-title":"The urinary microbiome and bladder cancer","volume":"13","author":"Heidar","year":"2023","journal-title":"Life (Basel)"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700122","article-title":"Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors","volume":"7","author":"Yazawa","year":"2000","journal-title":"Cancer Gene Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202504688","article-title":"Gut Parabacteroides distasonis-derived indole-3-acetic acid promotes phospholipid remodeling and enhances ferroptosis sensitivity via the AhR-FASN axis in bladder cancer","volume":"12","author":"Li","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B126","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12896-025-00963-9","article-title":"Parabacteroides distasonis promotes CXCL9 secretion of tumor-associated macrophages and enhances CD8(+)T cell activity to trigger anti-tumor immunity against anti-PD-1 treatment in non-small cell lung cancer mice","volume":"25","author":"Fan","year":"2025","journal-title":"BMC Biotechnol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1093\/advances\/nmy119","article-title":"Milk and dairy product consumption and bladder cancer risk: A systematic review and meta-analysis of observational studies","volume":"10","author":"Bermejo","year":"2019","journal-title":"Adv Nutr"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70455","article-title":"Exploring fecal microbiota transplantation: Potential benefits, associated risks, and challenges in cancer treatment","volume":"9","author":"Ramesh","year":"2026","journal-title":"Cancer Rep (Hoboken)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"B130","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.3390\/biomedicines10081783","article-title":"Bacteria for treatment: Microbiome in bladder cancer","volume":"10","author":"Min","year":"2022","journal-title":"Biomedicines"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s12672-025-03296-3","article-title":"Gut microbiota and urological cancers: From microecological imbalance to potential for precision therapy","volume":"16","author":"Cui","year":"2025","journal-title":"Discov Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-082323-114522","article-title":"Harnessing the microbiome in cancer immunotherapy: Regulation, prediction, and therapeutic targeting","volume":"44","author":"Zarour","year":"2025","journal-title":"Annu Rev Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02803-3","article-title":"Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma","volume":"30","author":"Bj\u00f6rk","year":"2024","journal-title":"Nat Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13073-017-0409-1","article-title":"Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients","volume":"9","author":"Galloway-Pe\u00f1a","year":"2017","journal-title":"Genome Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313017","article-title":"European consensus conference on faecal microbiota transplantation in clinical practice","volume":"66","author":"Cammarota","year":"2017","journal-title":"Gut"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00285-3","article-title":"Engineering living therapeutics with synthetic biology","volume":"20","author":"Cubillos-Ruiz","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-0437-6","article-title":"Live biotherapeutic products: The importance of a defined regulatory framework","volume":"52","author":"Cordaillat-Simmons","year":"2020","journal-title":"Exp Mol Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1920567\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:10:30Z","timestamp":1789639830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1920567\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":139,"alternative-id":["10.3389\/fimmu.2026.1920567"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1920567","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1920567"}}